There was an overall statistically significant difference in OS between the three arms : median OS in months was 10.5 ( 8.3-20 .2 ) for pemetrexed , 8.0 ( 6.8-13 .5 ) for sunitinib , and 6.7 ( 4.1-10 .1 ) for the combination ( p = 0.03 ) .